Advertisement
Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) said Monday it currently expects that its financial results for the second quarter 2024 will include an acquired in-process research and development charge of approximately $24 million on a pre-tax basis.
This charge relates to up-front payments, as well as a premium on equity securities purchased, in connection with collaboration and licensing agreements.
This charge is expected to negatively impact each of GAAP and non-GAAP net income per share for the second quarter 2024 by approximately $0.18.
read more
Regeneron Pharma Q2 Results Top Estimates - Update
Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews
|
387 dias atrás
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews
|
421 dias atrás
Regeneron Pharma Q4 Results Top Estimates - Update
Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.
RTTNews
|
568 dias atrás
Regeneron Completes Acquiring Sanofi's Stake In Libtayo
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews
|
1149 dias atrás
U.S. Dollar Drops After Powell's Speech
The U.S. dollar weakened against its major counterparts in the New York session on Friday, as Federal Reserve Chair Jerome Powell hinted at a potential rate cut next month.
RTTNews
|
12h 10min atrás
TSX Hits New Record High As Stocks Rally On Fed Rate Cut Hopes
The Canadian market is up firmly in positive territory a little past noon on Friday, with stocks from across several sectors moving higher on strong buying support amid rising hopes of an interest rate cut by the Federal Reserve in September.
RTTNews
|
17h 40min atrás
Powell Says Outlook, Shifting Balance Of Risks 'May Warrant' Lower Rates
Federal Reserve Chair Jerome Powell delivered a highly-anticipated speech before the Jackson Hole Economic Symposium on Friday, although he touched only briefly on the outlook for monetary policy. "With policy in restrictive territory, the baseline outlook and the shifting balance of risks may warrant adjusting our policy stance," Powell said.
RTTNews
|
19h 49min atrás
Bay Street Likely To Open On Mixed Note; Powell's Speech Eyed
Canadian shares are likely to open on a somewhat mixed note Friday morning with investors awaiting Fed Chair Jerome Powell's speech at Jackson Hole. Lower commodity prices may weigh a bit early on in the session.
RTTNews
|
22h 19min atrás
